The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: A case-control study within the prospective EPIC cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 4, 2012, Pages 619-628

  Grote, Verena A ^a   Nieters, Alexandra ^a,b   Kaaks, Rudolf ^a   Tjnøneland, Anne ^c   Roswall, Nina ^c   Overvad, Kim ^d   Skjelbo Nielsen, Michael R ^e   Clavel Chapelon, Franco̧ise ^f,g   Boutron Ruault, Marie Christine ^f,g   Racine, Antoine ^f,g   Teucher, Birgit ^a   Lukanova, Annekatrin ^a   Boeing, Heiner ^h   Drogan, Dagmar ^h   Trichopoulou, Antonia ^i,j   Trichopoulos, Dimitrios ^j,k,l   Lagiou, Pagona ^i,k,l   Palli, Domenico ^m   Sieri, Sabina ⁿ   Tumino, Rosario ^o   Vineis, Paolo ^p,q   Mattiello, Amalia ^r   Suaŕez, Marcial Vicente Arguëlles ^s   Duell, Eric J ^t,u   Sańchez, Mariá José ^u,v   Dorronsoro, Miren ^u,w   Castanõ, José María Huerta ^u,x   Barricarte, Aurelio ^u,y   Jeurnink, Suzanne M ^z,aa   Peeters, Petra H M ^q,z   Sund, Malin ^ab   Ye, Weimin ^ab,ac   Regner, Sara ^ad,ae   Lindkvist, Bjor̈n ^af   Khaw, Kay Tee ^ag   Wareham, Nick ^ah   Allen, Naomi E ^ai   Crowe, Francesca L ^ai   Fedirko, Veronika ^aj   Jenab, Mazda ^aj   Romaguera, Dora ^q   Siddiq, Afshan ^q   Bueno de Mesquita, H Bas ^z,aa   Rohrmann, Sabine ^a,ak   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

ⁱ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^j HELLENIC HEALTH FOUNDATION   (Greece)

^k BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^l HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^m CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

ⁿ NATIONAL CANCER INSTITUTE   (Italy)

^o CIVILE M P AREZZO HOSPITAL   (Italy)

^p HuGeF Foundation   (Italy)

^q IMPERIAL COLLEGE LONDON   (United Kingdom)

^r UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^s PUBLIC HEALTH DIRECTORATE   (Spain)

^t HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^u CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^v ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^w Basque Government   (Spain)

^x Murcia Regional Health Authority   (Spain)

^y INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^z UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^aa NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^ab UMEÅ UNIVERSITY   (Sweden)

^ac KAROLINSKA INSTITUTE   (Sweden)

^ad UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^ae LUND UNIVERSITY HOSPITAL   (Sweden)

^af UNIVERSITY OF GOTHENBURG   (Sweden)

^ag UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ah MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^ai UNIVERSITY OF OXFORD   (United Kingdom)

^aj INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^ak UNIVERSITY OF ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; LYSINE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITION; PANCREAS CANCER; PANCREAS SECRETION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADULT; AGED; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC;

EID: 84859388699     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-1139     Document Type: Article

References (26)

1. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37:586-600. (Pubitemid 28231153)
2. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46. (Pubitemid 32156196)
3. Mendez JD, Xie J, Aguilar-Hernandez M, Mendez-Valenzuela V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem 2010;341:33-41.
4. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008;22:1572-80. (Pubitemid 351656797)
5. Santilli F, Vazzana N, Bucciarelli LG, Davi G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009;16:940-52.
6. Kalea AZ, Schmidt AM, Hudson BI. Alternative splicing of RAGE: roles in biology and disease. Front Biosci 2011;17:2756-70.
7. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007;7:777-89.
8. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009;52:2251-63.
9. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008;14:940-5. (Pubitemid 351753280)
10. Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 2010;31:334-41.
11. Krechler T, Jachymova M, Mestek O, Zak A, Zima T, Kalousova M. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem 2010;43:882-6.
12. Jiao L, Weinstein SJ, Albanes D, Taylor PR, Graubard BI, Virtamo J, et al. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res 2011;71:3582-9.
13. Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, Boeing H, et al. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2002;5:1147-62. (Pubitemid 36313610)
14. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24. (Pubitemid 36313608)
15. Grote VA, Rohrmann S, Nieters A, Dossus L, Tjonneland A, Halkjaer J, et al. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 2011;54:3037-46.
16. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2003;6:407-13. (Pubitemid 36749764)
17. Kalea AZ, See F, Harja E, Arriero M, Schmidt AM, Hudson BI. Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling. Cancer Res 2010;70:5628-38.
18. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2011;20:1430-8.
19. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008;7:29.
20. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-109. (Pubitemid 36399105)
21. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010;17:666-76.
22. Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ, Tan KC. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 2011;120:81-9.
23. Semba RD, Arab L, Sun K, Nicklett EJ, Ferrucci L. Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults. J Nutr 2011;141:1726-30.
24. Rothman KJ, Greenland S, Lash TL. Design strategies to improve study accuracy. In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. p. 179-81.
25. Semba RD, Ferrucci L, Fink JC, Sun K, Beck J, Dalal M, et al. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 2009;53:51-8.
26. Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, et al. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 2005;18:1385-96. (Pubitemid 41348659)